Synovial sarcoma is characterized cytogenetically by the nonrandom translocation t(X;18) (p11.2-q11.2), which generates the fusion of two genes, SYT on chromosome 18 and one of the SSXs on chromosome Xp11.2, where five highly homologous genes (SSX1 to SSX5) have been so far described. Three different types of translocation have been identified in synovial sarcoma, involving SSX1, SSX2, and SSX4. To date, in the literature, only three cases of SYT-SSX4 have been reported, one by Skytting et al. (1) , one by our group (2) , and one by Brodin et al. (3) .
Recently, our laboratory identified an additional case of SYT-SSX4. After receiving written informed consent from the patient, we therefore analyzed the snap-frozen samples from the two synovial sarcomas, monophasic in subtype, by reverse transcription-polymerase chain reaction, specifically amplifying the SYT-SSX4 chimeric transcript following the procedures of Skytting et al.
(1) (Fig. 1, A) .
It is interesting that both of our cases harbored an SSX4 gene breakpoint different from that described by the other investigators (1, 3) . In fact, a 487-basepair (bp) band was detected after a nested polymerase chain reaction. The sequence analysis revealed that the fusion transcript consisted of 66 bp of the SYT gene followed by 421 bp of the SSX4 gene ( Fig. 1, B) . The alignment of this sequence with both SYT (GenBank accession number X79201) and SSX4 (GenBank accession number NM_005636) complementary DNA (cDNA) sequences revealed that the SYT breakpoint was located at the same position as the most common SYT-SSX fusion transcripts (4) . By contrast, the SSX4 gene break at position 70, between exons 1 and 2, was at variance with the one detected by Skytting et al. (1) , which was interrupted at position 331 of the same cDNA sequence (GenBank accession number NM_005636).
At the level of the amino acid sequence, this new variant retains the majority of the Krüppel associated box (KRAB)-like domain present in the 5Ј portion of the SSX gene (aa 20 to 83), a region thought to be involved in transcriptional repression activity. Although the SSX repression domain (SSXRD) located in the last 34 residues of the Cterminus of the protein also seems to be responsible for transcriptional repression (5), it is tempting to speculate that the KRAB-like-containing N-terminal portion of the SSX protein may affect the activity of the chimeric protein on transactivation of different target genes.
Since, to our knowledge, only one variant each of fusion transcripts from SYT-SSX1 and SYT-SSX2 has been described to date (6, 7) , strongly implying that the rearrangement involved in these cases is a constant and reproducible mechanism, the SYT-SSX4 translocation seems to present a high breakpoint variability (three of four cases examined) despite its relatively low frequency. Thus, this correspondence contributes to a better estimation of the SYT-SSX4 rearrangement frequency by the identification of a set of primers spe- 
RESPONSE
The SYT-SSX4 variant demonstrated by Agus et al. is novel and differs from hitherto known SYT-SSX transcripts in the sense that SYT is fused to exon 2 of SSX4 instead of to exon 5. Consequently, parts of the Krüppel associated box (KRAB) domain (located in exons 1 and 2) are present in this fusion transcript, which could have a functional impact since KRAB acts as a repressor.
Recently, we found a synovial sarcoma tumor exclusively expressing SYT-SSX4, in which SYT is fused to exon 6 of the SSX4 gene (unpublished results). Nevertheless, this tumor exhibited a highly malignant phenotype with early onset of metastatic disease. This finding is surprising, since exon 5, which is expressed in all SYT-SSXpositive synovial sarcomas reported so far, has been proposed to be important for the transforming ability of SYT-SSX. The major base-pair (bp) differences between SYT-SSX1, SYT-SSX2, and SYT-SSX4, which otherwise are very homologous, are found in the socalled divergent domain (DD) within this exon (1). (Our investigations on synovial sarcoma patients, including this patient, have been approved by a National Ethical Committee, and we received written informed consent from the patient.) It has been suggested that this region may underlie the biologic differences between SYT-SSX1 and SYT-SSX2. The absence of exon 5 in the present tumor suggests that the transforming potential of the SYT-SSX fusion protein cannot be restricted to this part of the molecule. The SSX repressor domain (SSXRD), which is responsible for the repression of transcription (2) , is located in exon 6. This region has also been shown to be responsible for the distribution of the SSX protein in the cell nucleus (1) . Therefore, this part of SYT-SSX has also been proposed to play a crucial role in the development of synovial sarcomas. However, this contradicts the finding of Sonobe et al. (3) , who identified a synovial sarcoma tumor carrying an exon 6-truncated variant of SYT-SSX1, which lacks the 240 bp of the 3Ј portion of SSX including SSXRD. All results taken together, therefore, indicate that SSX is not per se involved in the transforming process of SYT-SSX. Instead, the SYT portion, which in fact contains transcriptionactivating regions (3), might be critical in this respect, and perhaps the transactivating ability of SYT is augmented because of conformational changes following fusion with the SSX gene. The recent finding that SYT-SSX is linked functionally to the transcriptional regulatory machinery involving hBRM/ hSNF2a (4) discloses a complex scenario in which protein-protein interactions, suppression, and activation of target genes may play an integrated role in the development of synovial sarcoma.
In agreement with the finding of Agus et al., we stress the fact that several unexpected SYT-SSX variants can be demonstrated in otherwise reverse transcription-polymerase chain reaction (RT-PCR)-negative cases by use of an optimized RT-PCR approach. For example, it should be noted that the use of consensus primers for SYT-SSX with SSX primers specific for the 3Ј end of exon 6 could miss fusion gene variants. This is illustrated by the exon 6-truncated SYT-SSX variant described by Sonobe et al. (3) . Using optimized RT-PCR, we believe that several novel and unexpected SYT-SSX variants will be discovered in the future. Probably, tumors expressing SYT-SSX4 transcripts are much more represented than the few reported so far (Fig. 1) .
BERTHA BRODIN MARIA TÖ RNKVIST KARL HASLAM YUNTAO XIE ARMANDO BARTOLAZZI OLLE LARSSON Fig. 1 . Schematic presentation of SYT-SSX4 transcripts identified so far. The localization of KRAB (i.e., Krüppel associated box), DD (i.e., divergent domain), and SSXRD (i.e., SSX repressor domain) is indicated above the SSX4 boxes. The first case shows coexistence of two SYT-SSX4 transcripts (6); the upper one represents the full-length SYT-SSX4, and the lower one represents the splice variant missing exon 5.
